Skip to content
Review Open access

Heart Failure and Cancer: Incidence and Mortality Patterns, A Systematic Review and Meta-analysis.

Aug 2026 · European Journal of Heart Failure · 0 citations
Medicine

TL;DR

The observed HF-cancer association is influenced by statistical methodology, shared risk factors, differences in surveillance intensity and cancer type, that confound analyses investigating possible causal biological links.

Abstract

Background

Cancer and heart failure (HF) frequently coexist due to population ageing and improved survival for both conditions. HF is a well-recognised complication of oncologic therapies and a potential association between HF and subsequent cancer incidence has been recently noticed. We therefore conducted a meta-analysis to quantify cancer incidence and mortality in patients with and without HF.

Methods

Databases were searched from inception to 15 February 2026. Data from observational studies and randomised trials on individuals with and without HF and reporting cancer incidence and/or mortality during follow-up were included. The main outcome of interest was the incidence of any cancer; secondary outcomes included site-specific cancer incidence (lung, colorectal, breast, and prostate) and all-cause, cardiovascular, and cancer-related mortality.

Results

Twelve studies comprising 8,979,195 individuals were included. HF was associated with a higher incidence of cancer (hazard ratio [HR] 1.33, 95% confidence interval [CI] 1.14-1.54), with substantial heterogeneity (I2 = 99.7%). Cancer site-specific analyses showed increased incidences of lung (HR 1.70, 95% CI 1.26-2.29), colorectal (HR 1.28, 95% CI 1.11-1.48), and breast (HR 1.19, 95% CI 1.04-1.37), but not prostate, cancer. Effect estimates varied according to analytical strategy: matched HF and non-HF cohorts reported higher risk estimates than those using covariate adjustment without matching. Mortality data were sparse and heterogeneous.

Conclusions

HF is associated with a higher incidence of cancer, although with marked heterogeneity among studies and cancer types. Mortality and cause of death were rarely reported. The observed HF-cancer association is influenced by statistical methodology, shared risk factors, differences in surveillance intensity and cancer type, that confound analyses investigating possible causal biological links. More granular and harmonised studies are required.

Read PDF

Similar papers

Review Open access Aug 2026

Incidence of and mortality risk from cardiovascular diseases after a cancer diagnosis: An umbrella review

A substantial cardiovascular burden among cancer patients is confirmed while highlighting important limitations in the evidence base, and strengthening integrated cardio-oncology care and prioritising high-quality research are essential to improve risk stratification and patient outcomes.

S. A. Belachew, S. A. Mohammed, G. Garvey · 0 citations
Review Aug 2026

Impact of cardiovascular disease on cancer incidence and mortality

The manifold of CVD and CV health indicators increase the risk of new-onset cancer and cancer-related mortality, and the need for awareness of future cancer in patients with CVD is emphasized.

L. Yousif, P. Ameri, M. Vinci et al. · 0 citations
Open access Sep 2026

Excess hypertension-related mortality among cancer patients in the United States: a SEER-based study

Cancer remains a leading cause of mortality globally, while hypertension is the primary contributor to cardiovascular disease and premature death. These conditions frequently coexist; hypertension may precede cancer due to shared risk factors or arise during or after cancer treatment, partly as a result of the hypert...

Bahaa Mali, Ali Mali, Alaa Mali et al. · 0 citations
Open access Aug 2026

An analysis of heart failure among cancer patients in the United States between 1999 and 2020

There is a substantial HF-related mortality burden across cancer patients, which is on the rise in recent years, and certain high-risk populations may be identified and cardio-oncology surveillance and targeted cardiovascular risk reduction strategies may be implemented among cancer survivors.

Abes A. Bautista Neughebauer, D. Talreja, A. Gaitanidis · 0 citations
Aug 2026

Cardiovascular disease in breast cancer patients receiving chemotherapy: epidemiology and risk factors

Evaluating the occurrence of new-onset CVD in women with breast cancer undergoing chemotherapy and identifying factors associated with increased risk of cardiovascular disease highlights the need for sustained cardiovascular surveillance in breast cancer survivors.

V. Dvorovy, L. Kováčová, M. Selvek et al. · 0 citations
Review Aug 2026

Risk factors for cardiovascular diseases and predictors of complications in patients with lung cancer

It is recommended that patients with lung cancer undergo screening to assess their cardiovascular risk and related complications and it is recommended that patients with lung cancer undergo screening to assess their cardiovascular risk and related complications.

M. Mamedov, P. Skopin, A. K. Karimov · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.